Skip to main content

Table 3 Univariate and multivariate analysis of risk factors for locoregional recurrence (LRR), overall survival (OS) and disease-free survival (DFS) in entire cohort

From: Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

Variables Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
5-year LRR % (events) P HR (95%CI) P 5-year OS % (events) P HR (95%CI) P 5-year DFS % (events) P HR (95%CI) P
Treatment center
 Cohort 1 6.1 (152)   1.00   93.9 (148)   1.00   85.5 (367)   1.00  
 Cohort 2 7.5 (97) .229 0.94 (0.73–1.23) .675 91.6 (105) .012 1.08 (0.86–1.37) .491 83.5 (216) .672 0.87 (0.73–1.04) .122
Year
 1999–2008 7.6 (142)   1.00   91.5 (158)   1.00   82.8 (328)   1.00  
 2009–2014 5.6 (107) .033 1.00 (0.76–1.33) .980 94.9 (95) < .001 0.79 (0.61–1.03) .079 86.7 (255) < .001 0.88 (0.74–1.06) .187
Age (years)
 ≤ 40 9.6 (65)   1.00   92.6 (52)   1.00   81.0 (134)   1.00  
 > 40 5.9 (184) .002 0.61 (0.48–1.80) < .001 93.2 (201) .184 0.77 (0.61–0.97) .026 85.8 (449) .013 0.74 (0.62–0.87) < .001
T stage
 T1 3.9 (70)   1.00   94.9 (87)   1.00   89.6 (188)   1.00  
 T2 9.1 (179) < .001 1.87 (1.47–2.38) < .001 91.4 (166) < .001 1.58 (1.28–1.93) < .001 80.6 (396) < .001 1.58 (1.36–1.83) < .001
SLNB
 No 7.6 (240)   1.00   92.9 (250)   1.00   84.7 (568)   1.00  
 Yes 6.2 (9) .635 2.24 (1.23–4.09) .008 98.1 (3) .046 0.83 (0.36–1.92) .670 90.1 (15) .103 1.11 (0.69–1.80) .659
No. of ALND
 ≤ 19 7.2 (73)   1.00   92.3 (183)   1.00   83.4 (411)   1.00  
 > 19 5.5 (76) .200 0.85 (0.66–1.08) .186 94.6 (70) .012 0.78 (0.63–0.97) .029 87.7 (171) .008 0.82 (0.70–0.96) .013
No. of positive nodes
 1 5.8 (112)   1.00   94.0 (115)   1.00   85.8 (281)   1.00  
 2 7.1 (80)   1.53 (1.19–1.97) .001 92.9 (77)   1.21 (0.97–1.51) .084 84.5 (179)   1.18 (1.01–1.39) .041
 3 8.0 (57) .002 1.77 (1.33–2.36) < .001 90.8 (61) .049 1.43 (1.12–1.84) .004 82.9 (123) .006 1.32 (1.09–1.58) .004
Lymphovascular invasion
 No 6.1 (189)   1.00   93.5 (195)   1.00   85.8 (447)   1.00  
 Yes 8,7 (37)   1.27 (0.92–1.75) .146 91.5 (32)   1.03 (0.75–1.42) .851 80.7 (82)   1.16 (0.93–1.44) .196
 Unknown 8.5 (23) .053 0.76 (0.48–1.21) .254 90.4 (26) .100 0.92 (0.64–1.33) .655 80.3 (54) .056 0.92 (0.69–1.24) .590
Histological grade
 I- II 4.8 (103)   1.00   94.6 (110)   1.00   87.8 (266)   1.00  
 III 10.3 (83)   1.41 (1.08–1.84) .011 91.4 (76)   1.35 (1.06–1.71) .014 81.6 (172)   1.20 (1.01–1.43) .042
 Unknown 8.6 (63) < .001 1.21 (0.87–1.69) .259 90.7 (67) < .001 1.03 (0.77–1.37) .851 80.5 (145) < .001 1.10 (0.89–1.35) .389
Surgery type
 MRM 7.0 (240)   1.00   92.7 (241)   1.00   84.0 (557)   1.00  
 BCS 2.3 (9) .001 1.00 (0.54–1.86) .996 96.5 (12) .001 1.19 (0.72–1.99) .495 92.9 (27) < .001 0.79 (0.55–1.14) .204
Radiotherapy
 No 7.6 (209)   1.00   92.5 (202)   1.00   84.1 (445)   1.00  
 Yes 3.8 (40) < .001 0.42 (0.29–0.59) < .001 94.7 (51) < .001 0.62 (0.46–0.83) .001 86.8 (138) .001 0.77 (0.64–0.94) .009
Chemotherapy
 No 4.7 (10)   1.00   89.1 (23)   1.00   83.9 (35)   1.00  
 Yes 6.7 (239)   0.96 (0.44–2.09) .922 93.3 (229)   0.40 (0.22–0.71) .002 84.9 (546)   0.52 (0.33–0.80) .003
 Unknown 0 (0) .546 0.58 (0.07–4.55) .606 94.4 (1) < .001 0.23 (0.03–1.69) .149 88.9 (2) .003 0.28 (0.07–1.17) .081
Chemotherapeutic drug
 Taxane-based 6.1 (142)   1.00   94.5 (123)   1.00   86.4 (324)   1.00  
 Others 8.6 (88)   1.42 (1.08–1.87) .011 90.6 (95)   1.22 (0.96–1.56) .103 80.7 (201)   1.20 (1.01–1.44) .041
 Unknown 4.5 (19) .005 0.87 (0.48–1.57) .614 91.4 (35) < .001 1.11 (0.66–1.88) .692 86.3 (58) < .001 0.89 (0.61–1.30) .551
Hormone receptor & Hormonal therapy
 negative & no 13.0 (106)   1.00   85.9 (108)   1.00   73.2 (223)   1.00  
 positive & yes 4.6 (118)   0.52 (0.40–0.66) < .001 95.6 (108)   0.44 (0.35–0.55) < .001 89.0 (286)   0.55 (0.47–0.65) < .001
 positive & no 6.5 (18)   0.49 (0.30–0.78) .003 90.5 (26)   0.78 (0.56–1.09) .153 81.7 (53)   0.67 (0.50–0.89) .005
 Unknown 6.1 () < .001 0.79 (0.43–1.47) .465 90.9 (11) < .001 0.59 (0.34–1.02) .060 82.4 (21) < .001 0.74 (0.50–1.11) .144
HER2 & Target therapy
 negative & no 5.7 (145)   1.00   94.1 (147)   1.00   86.5 (352)   1.00  
 positive & yes 4.9 (10)   0.84 (0.46–1.53) .578 98.6 (3)   0.44 (0.20–0.93) .032 90.2 (19)   0.63 (0.41–0.98) .038
 positive & no 12.0 (63)   1.55 (1.18–2.04) .002 87.7 (62)   1.35 (1.05–1.73) .017 75.7 (133)   1.33 (1.10–1.60) .003
 Unknown 6.1 (31) < .001 1.07 (0.77–1.50) .677 91.4 (41) < .001 1.13 (0.86–1.49) .374 84.3 (79) < .001 1.03 (0.83–1.27) .788
  1. Abbreviations: HR Hazard ratio, CI Confidence interval, SLNB Sentinel lymph node biopsy, ALND Axillary lymph node dissection, HER2 Human epidermal growth factor receptor 2
\